Group 1 - The core viewpoint of the article is that Kintor Pharmaceutical (01888) has released a positive profit forecast for the previous year, expecting a net profit increase of over 80% to more than 2.39 billion yuan, surpassing Citigroup's prediction of 2.14 billion yuan [1] - Citigroup has raised its earnings forecasts for Kintor Pharmaceutical for 2025, 2026, and 2027 by 8%, 6%, and 8% respectively, and has increased the target price from 20.5 HKD to 28 HKD [1] - The stock has risen over 50% year-to-date, and Citigroup believes this has largely reflected the positive profit forecast factors [1] Group 2 - Key catalysts for Kintor Pharmaceutical include the expectation of further increases in average selling prices in the first half of this year to keep pace with recent copper cost inflation [1] - After the 2025 earnings announcement, management is expected to provide more positive information regarding the development of AI glass fabric [1]
花旗：升建滔积层板(01888)目标价至28港元 盈喜胜预期